48 completed. 48 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 48 | Completed 48 |
| Phase 2 | 6 | Completed 6 |
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 CKD-846, D091 - Benign Prostate Hypertrophy(BPH) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 34 | 2026-02-23 | 2026-07-21 |
| A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers AD-116, AD-1161 - Benign Prostatic Hyperplasia | Phase 1 | Completed | Addpharma Inc. | 44 | 2026-01-22 | 2026-07-28 |
| BOTOX Injection Technique for LUTS Due to BPH Botulinum Toxin Type A (BoNT-A) - Benign Prostatic Hyperplasia | Phase 1 | Completed | Benha University | 60 | 2025-10-01 | 2026-06-12 |
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 CKD-846, D091 - Benign Prostate Hypertrophy(BPH) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2023-11-13 | 2026-01-14 |
| A 3 Months Duration Interventional Study Comparing Hemodynamic Parameters Between Bolus and Fractionated Group. 0.5% Heavy Bupivacaine - Prostatic Hyperplasia, Benign | Phase 1 | Completed | National Academy of Medical Sciences, Nepal | 72 | 2022-10-01 | 2024-10-08 |
| A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. BR9006-1, BR9006-2 - Benign Prostatic Hyperplasia (BPH), Overactive Bladder | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 36 | 2020-07-20 | 2020-10-28 |
| Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab. - Benign Prostatic Hyperplasia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2019-03-11 | 2020-01-30 |
| Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab. - Benign Prostatic Hyperplasia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2019-03-11 | 2020-01-30 |
| The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Taipei Veterans General Hospital, Taiwan | 23 | 2019-03-06 | 2020-04-13 |
| Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil Dutasteride 0.5 mg, Tadalafil 5 mg, YY-201 - Benign Prostatic Hyperplasia | Phase 1 | Completed | Yuyu Pharma, Inc. | 36 | 2017-03-27 | 2017-11-24 |
| A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 CTT1057, Prostatectomy - Prostate Cancer | Phase 1 | Completed | Cancer Targeted Technology | 20 | 2016-09-01 | 2017-11-06 |
| A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects Tadalafil, Dutasteride - Benign Prostate Hyperplasia | Phase 1 | Completed | Yuyu Pharma, Inc. | 28 | 2016-05-01 | 2017-04-04 |
| A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects CKD-397 - Benign Prostatic Hypertrophy (BPH) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 16 | 2015-12-01 | 2017-08-09 |
| Study to Compare the Safety and Pharmacokinetics of CKD-397 CKD-397, TD+TM - Benign Prostatic Hyperplasia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 36 | 2015-11-01 | 2016-01-12 |
| PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers HCP1303, HGP1201, HIP1402 - Erectile Dysfunction, Prostatic Hyperplasia | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 36 | 2015-10-01 | 2016-03-22 |
| Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects Dutasteride-Test product, Dutasteride-Reference product - Prostatic Hyperplasia | Phase 1 | Completed | GlaxoSmithKline | 36 | 2015-09-09 | 2018-06-19 |
| The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg - LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 54 | 2015-08-01 | 2016-06-24 |
| Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet - Prostatic Hyperplasia | Phase 1 | Completed | GlaxoSmithKline | 56 | 2015-07-30 | 2018-06-19 |
| Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers HCP1303, HGP1201, HIP1402 - Erectile Dysfunction, Prostatic Hyperplasia | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 30 | 2015-07-01 | 2016-03-18 |
| Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers JLP-1207(Fasted), JLP-1207(Fed) - LUTS, Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 54 | 2015-07-01 | 2016-06-24 |
Showing 20 of 48. Sign in to see all of them.
Urinary Bladder, Overactive (6) · Lower Urinary Tract Symptoms (5) · Erectile Dysfunction (4) · Fasting (1) · Nocturia (1) · Prostatic Diseases (1) · Prostatic Neoplasms (1) · Prostatitis (1) · Urinary Bladder Neck Obstruction (1) · Urinary Incontinence (1)
Genital Diseases (48) · Genital Diseases, Male (48) · Male Urogenital Diseases (48) · Urogenital Diseases (48) · Prostatic Diseases (47) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Urological Manifestations (10) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urinary Bladder Diseases (6) · Urologic Diseases (6) · Lower Urinary Tract Symptoms (5) · Mental Disorders (4) · Sexual Dysfunction, Physiological (4)
Tamsulosin (14) · Dutasteride (12) · Tadalafil (6) · Solifenacin Succinate (3) · Botulinum Toxins, Type A (2) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1) · Embryo Implantation (1) · Ethanol (1) · Finasteride (1) · PRX302 (1) · Photochemotherapy (1) · Prostatectomy (1) · QLT0074 (1) · Sildenafil Citrate (1) · Sodium Chloride (1)
GlaxoSmithKline (13) · Chong Kun Dang Pharmaceutical (6) · Hanmi Pharmaceutical Company Limited (3) · Jeil Pharmaceutical Co., Ltd. (3) · Boehringer Ingelheim (2) · Dongkook Pharmaceutical Co., Ltd. (2) · Yuyu Pharma, Inc. (2) · Addpharma Inc. (1) · Allergan (1) · American Medical Systems (1) · Astellas Pharma Europe B.V. (1) · Benha University (1) · Boryung Pharmaceutical Co., Ltd (1) · Cancer Targeted Technology (1) · Eli Lilly and Company (1)
South Korea (15) · United States (11) · Australia (3) · Brazil (2) · Germany (2) · Canada (1) · China (1) · Egypt (1) · Japan (1) · Nepal (1) · Netherlands (1) · Russia (1) · Singapore (1) · Taiwan (1)
Kyung-sang Yu, M.D., Ph.D. (2) · Min Kyu Park, MD, PhD (2) · Minsu Park, M.D., Ph.D. (2) · Yu-Jung Cha (2) · An-Hye Kim (1) · Beatrice Langton-Webster, PhD (1) · Georg Golor, PD Dr. med. (1) · Hyeong-Seok Lim, M.D.,Ph.D. (1) · Ji-Young Park, MD, PhD (1) · Kyung-sang Yu, M.D.,Ph.D. (1)